Charles River Laboratories International (CRL) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Charles River Laboratories International (NYSE: CRL):

• 10/12/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $300.00 to $340.00. They now have an “overweight” rating on the stock.
• 10/2/2026 – Charles River Laboratories International was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/30/2026 – Charles River Laboratories International is now covered by UBS Group AG. They set a “buy” rating and a $357.00 price target on the stock.
• 9/30/2026 – Charles River Laboratories International was upgraded by UBS Group AG to “strong-buy”.
• 9/28/2026 – Charles River Laboratories International had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/28/2026 – Charles River Laboratories International had its price target raised by Jefferies Financial Group Inc. from $305.00 to $340.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Charles River Laboratories International had its price target raised by Deutsche Bank Aktiengesellschaft from $300.00 to $320.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Charles River Laboratories International was given a new $330.00 price target by Evercore Inc.
• 9/25/2026 – Charles River Laboratories International had its price target raised by TD Cowen from $300.00 to $325.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Charles River Laboratories International had its price target raised by Barclays PLC from $300.00 to $330.00. They now have an “overweight” rating on the stock.
• 9/25/2026 – Charles River Laboratories International had its price target raised by Royal Bank Of Canada from $282.00 to $322.00. They now have an “outperform” rating on the stock.
• 9/25/2026 – Charles River Laboratories International had its price target raised by Mizuho from $264.00 to $295.00. They now have a “neutral” rating on the stock.
• 9/25/2026 – Charles River Laboratories International had its price target raised by Robert W. Baird from $291.00 to $334.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Charles River Laboratories International was given a new $330.00 price target by Argus.
• 9/11/2026 – Charles River Laboratories International had its “outperform” rating reaffirmed by Evercore Inc. They now have a $320.00 price target on the stock.

Insider Buying and Selling

In related news, Director James C. Foster sold 33,561 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the sale, the director directly owned 31,596 shares in the company, valued at approximately $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 91,971 shares of company stock valued at $26,033,968 in the last ninety days. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.